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1. Introduction 
Lipoprotein(a) [Lp(a)] is a plasma lipoprotein whose structure and composition closely 
resembles that of low density lipoprotein (LDL), but with one of additional molecule of 
apolipoprotein(a) [apo(a)], a large glycoprotein linked to apoB by a disulfide bond (Figure 1) 
[1, 2]. High Lp(a) levels have been established as an independent risk factor for 
atherocslerosis [3-5], and Lp(a) deposits have been found in atherosclerotic lesions but not in 
normal arterial walls [6-8].  
Lp(a) can be modified by oxidation in vitro, and then be taken up by macrophages by means 
of scavenger receptors, where it promotes their transformation into foam cells within the 
arterial walls [9-13]. Oxidized Lp(a) [ox-Lp(a)] may also induce adhesion molecular 
expression on monocytes, promoting their recruitment and adhesion to the endothelium 
[14], and influence the responsiveness of platelets to various agonists [15]. Modified forms of 
Lp(a), some resembling oxidized Lp(a), have been identified in human atheromatous lesions 
[16]. In addition, ox-Lp(a) causes significant changes in apo(a) conformation, which could 
enhance the interaction of these particles with plasminogen binding sites as well as 
macrophage scavenger receptors, resulting in increased inhibitory effect on plasminogen 
activation and finally leading to attenuate fibrinolytic activity [17].  
Ox-Lp(a) has been reported to play more potent role than native Lp(a) in atherosclerosis [10, 
14, 17, 18], and autoantibodies against ox-Lp(a), Lp(a) immune complexes [Lp(a)-IC] have 
also been detected in vivo simultaneously [19, 20]. The present review article focuses 
specifically on the relationship between Lp(a) oxidation, autoimmune and atherosclerosis 
together with our recent work.  
2. The pathogenic role of oxidized Lp(a)  
Lp(a) contains a large specific glycoprotein called apo(a), attached by a single disulfide 
bridge to apoB100 of LDL (Figure 1). The adverse cardiovascular qualities of Lp(a) have been 
related to both its LDL-like properties (i.e., formation of foam cells) and its presumed role in 
fibrinolysis.  
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3. Lp(a) oxidation  
The structure, fatty acid composition, and antioxidant concentrations of Lp(a) and LDL are 
quite similar [21]. In vitro studies have shown that Lp(a) can be modified by oxidation (both 
chemical and cellular-mediated) in a fashion similar to LDL [22]. This modification, which 
involved lipid peroxidation measured as thiobarbituric acid-reactive substances (TBARS), 
caused marked changes in the structure and biological properties of Lp(a). Relative to native 
Lp(a), oxidized particles showed decreases of free amino groups and protein fragmentation, 
increased negative charge, and high aggregation ability. They were taken up and degraded 
readily by human monocyte/macrophages by means of scavenger receptors, a known 
pathway for clearance of ox-LDL in atheroma, inducing cholesteryl ester accumulation and 
promoting their transformation into foam cells within the arterial walls [9-13]. Similar to 
above-mentioned pathway, ox-Lp(a) might, in part, form aggregation and contribute to foam 
cell formation by additional macrophage uptake mechanism, like phagocytosis [9]. Ox-Lp(a) 
may also induce adhesion molecular expression on monocytes, promoting their recruitment 
and adhesion to the endothelium and stimulating intimal monocytes to differentiate into 
resident macrophages [14]. Moreover, subsequent to the induction of oxygen-derived radicals, 
oxidized Lp(a) may impair endothelium-dependent vasodilation [23].  
4. Lp(a) and fibrinolysis 
Besides above atherogenic potential, ox-Lp(a) might favor an impaired fibrinolytic activity 
as it has been shown through its inhibitory effect on plasminogen binding to monocyte-like 
cells and the induction of plasminogen activator inhibitor-1 (PAI-1) overproduction in 
cultured human umbilical vein endothelial cell. Several plausible mechanisms were 
proposed to explain the anti-fibrinolytic potential of Lp(a) [24]. A considerable part of the 
anti-fibrinolytic properties of apo(a) seemed to reside in its molecular similarity to 
plasminogen [25]. Lp(a) inhibited plasminogen binding and activation at the surface of 
stabilized fibrin, endothelial cells and platelets in a dose-dependent fashion [25]. 
Oxidative modification of Lp(a) causes significant changes in apo(a) conformation, resulting 
in enhanced interaction of these particles with plasminogen binding sites and macrophage 
scavenger receptors [17]. These findings were supported by some clinical studies. Pepin et 
al. [8] found that Lp(a) in atherosclerotic lesions was oxidized, and the oxidized Lp(a) could 
be a more tightly bound fraction than apoB. Two studies reported large variations in the 
lysine binding capacity of Lp(a) purified from different individuals [26, 27]. This 
heterogeneity appeared not to be associated with apo(a) isoforms. Wang et al. [28] 
developed an enzyme-linked sandwich immunosorbent assay (ELISA) to determine Lp(a)-
associated plasminogen epitopes. The Lp(a)-associated plasminogen epitopes levels and this 
plasminogen epitopes to Lp(a) ratio have been found significantly increased in patients with 
hemodialysis, which may also be caused by the oxidative modification of Lp(a). In addition, 
Lp(a), especially in oxidized form, increases over two-fold the endothelial synthesis and 
secretion of PAI-1 in vitro, especially for the 2/2 PAI-1 genotype [29, 30].  
5. Oxidized Lp(a) in vivo and autoantibody 
The role of autoimmune-mediated pathways in the development of atherosclerosis has been 
the focus of much interest. Circulating ox-LDL and malondialdehyde (MDA) modified LDL 
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(MDA-LDL) have been reported to be useful markers for identifying coronary artery disease 
(CAD) [31-33]. Some studies support the relationship of increased levels of antibodies to ox-
LDL with the severity of atherosclerosis and future development of myocardial infraction 
[34], although the pathogenic role of these antibodies in atherosclerosis is controversial.  
Similarly, there is evidence supporting the presence of ox-Lp(a) in vivo. Thus, modified 
forms of Lp(a), some resembling ox-Lp(a) and some possibly degraded, have been identified 
in extracts of human advanced atherosclerotic plaques [16]. Romero et al. [35] reported the 
existence of autoantibodies against MDA-Lp(a) in vivo. Their study found the fact that most 
anti-MDA-Lp(a) also react against MDA-LDL and suggested the involvement of a common 
epitope in the reactivity of the majority of antibodies against these oxidatively modified 
lipoproteins, which might be caused by the existence of antibodies against modified apoB. 
While some patients were found seropositive for only one or the other autoantibodies 
against LDL or Lp(a), which supported the hypothesis of the existence of a separate 
antibody, which might be antibodies against modified apo(a).  
Wang et al. [36] have isolated and identified the ox-Lp(a) autoantibodies by an affinity 
chromatographic column of Sepharose 4B coupled with ox-Lp(a) from healthy subjects. All 
the isolated antibodies, after being fully absorbed by the ox-LDL column, showed different 
low reactivity with ox-LDL, while some of them still appeared high reactivity with ox-Lp(a), 
which suggested that autoantibody against ox-apo(a) exist in vivo and the isolated human 
autoantibodies against ox-Lp(a), which can recognize both apo(a) and apoB epitopes of ox-
Lp(a). 
6. Oxidized Lp(a) assay 
Apo(a) and apoB proteins of Lp(a) molecule can both be oxidatively modified in vivo. The 
degree of oxidized apo(a) or apoB protein of Lp(a) has been detected to estimate circulating 
ox-Lp(a) levels [37-40]. Yamada et al. [37] obtained a new 161E2 monoclonal antibody to 
react with oxidized Lp(a) but not with native Lp(a). The 161E2 monoclonal antibody was 
produced against synthetic peptide antigen, which was characterized as having various 
properties because its external exposure was induced as a result of oxidative modification. 
Using this antibody, they developed a ELISA to measure Lp(a) modified by oxidative stress, 
and found that hypertensive patients with complications showed a significantly higher level 
of oxidized Lp(a) in serum than did normotensive subjects, whereas there was no significant 
difference in native Lp(a) between normotensive and hypertensive subjects. Morishita R et 
al. [38] reported that ox-Lp(a) level in CAD patients with diabetes mellitus was significantly 
higher than in healthy volunteers. Moreover, serum ox-Lp(a) concentration showed a 
significant positive correlation with pulse wave velocity, an index of arteriosclerosis . Of 
importance, the deposition of oxidized Lp(a) was readily detected in calcified areas of 
coronary arteries in patients with myocardial infarction. 
Podrez et al. [39] also found that oxidized apoB protein of plasma Lp(a) was a characteristic 
of the patients with end-stage renal disease undergoing continuous ambulatory peritoneal 
dialysis. Interestingly, from apolipoprotein E-receptor deficient mice, Tsimikas et al. [40] 
cloned the natural murine monoclonal IgM autoantibody E06, which could bind the cell-
wall polysaccharide and prevent the uptake of oxidized LDL and apoptotic cells by 
scavenger receptors of macrophages. The plasma oxidized phospholipid was measured with 
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the use of the murine monoclonal antibody E06, and the result showed that oxidized 
phospholipids presented on particles of apo B-100 and primarily on Lp(a) lipoprotein 
correlated with both the presence and extent of angiographically documented coronary 
artery disease. However, neither of the above methods can simultaneously detect apo(a) and 
apoB epitopes of ox-Lp(a). 
Wang et al. [36] developed 2 “sandwich" ELISAs for measuring plasma ox-Lp(a) level, using 
human autoantibodies against ox-Lp(a) to capture ox-Lp(a) or polyclonal antibodies against 
ox-LDL to capture oxidized apoB of Lp(a), and then quantitating with monoclonal anti-
apo(a) enzyme conjugate, respectively. A significantly positive relationship was found 
between ox-Lp(a) levels detected by 2 ELISAs. Compared to control, plasma ox-Lp(a) levels 
in patients with CAD detected by 2 ELISAs were both significantly increased.  
7. The clinical value of circulating oxidized Lp(a) 
The mean levels of Lp(a), ox-Lp(a) and Lp(a)-IC were found much lower in newborns than 
in children and increased rapidly to that in children after birth. No difference of their levels 
was found in each of the 13 year groups in the children (Figure 2) [41]. The fact that ox-Lp(a) 
and Lp(a)-IC were present in all the healthy children and especially in newborns was also 
supported by other studies [42-44], and anti-ox-LDL antibodies and LDL-IC were also easily 
detectable in asymptomatic young adults and children [45, 46], suggesting that the immune 
response to modified lipoproteins could appear very early in the process, perhaps play an 
initiating role in atherosclerotic process. 
It is reported that ox-Lp(a) concentrations increased in CAD patients [36] and in rheumatoid 
arthritis patients with excessive cardiovascular events [47]. Moreover, the concentration of 
serum apo(a) epitope of ox-Lp(a) was reported to be significantly increased in hypertensive 
patients with complications and CAD patients with diabetes mellitus [37, 38]. ApoB protein 
of plasma Lp(a) was also found oxidized and was a characteristic of the patients with end-
stage renal disease undergoing continuous ambulatory peritoneal dialysis [39]. Thus, it is 
noteworthy to investigate the causal role of ox-Lp(a) in atherosclerotic cardiovascular 
disease in a prospective study and to explore the exact pathogenic role of ox-Lp(a). 
Several studies have found that ox-Lp(a) concentrations increased in both the ACS and 
stable CAD patients [48-50]. Interestingly, ox-Lp(a) concentrations and the ratios of ox-
Lp(a)/Lp(a) were significantly higher in the ACS patients than those in the stable CAD 
patients as well as control, while they remained similar between the stable CAD and control, 
which suggested that the increased ox-Lp(a) concentrations might mainly be attributable to 
the occurrence of ACS. Furthermore, ox-Lp(a) levels were found to be associated with a 
graded increase in the extent of CAD in the patients with ACS, while not in the stable CAD 
[48]. In addition, Wang et al. [49] have evaluated clinical value of ox-Lp(a) levels detected by 
the 2 assays for measuring plasma ox-Lp(a) level using autoantibody against ox-Lp(a) [ox-
Lp(a)1] or ox-LDL [ox-Lp(a)2] in ACS and stable CAD patients. A significantly positive 
relationship was found between ox-Lp(a) levels detected by 2 assays. Receiver-operating 
characteristic (ROC) curve analysis (Figure 3) confirmed that the performance of the 
association of ox-Lp(a) 1 with ACS was significantly superior to those of ox-Lp(a)2, Lp(a) 
and LDL cholesterol; while the performances of ox-Lp(a)2, Lp(a) and LDL cholesterol with 
ACS were similar. The performance of the association between ox-Lp(a)1 and stable CAD 
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was also significantly superior to that between ox-Lp(a)2 and stable CAD. The ox-Lp(a) 
levels increased in CAD, especially in ACS, and might be one of the major contributing 
factors for the development of atherosclerosis. In addition, the autoantibody was isolated 
from human mix serum and can recognize both apo(a) and apoB epitopes of ox-Lp(a), the 
developed ELISA for ox-Lp(a) by using autoantibody may more accurately reflect the state 
of Lp(a) oxidation in vivo. It is concluded that ox-Lp(a) levels using antibodies against ox-
Lp(a) might represent a better biochemical risk marker than those using antibodies against 
ox-LDL for ACS and stable CAD.  
Wang et al. [50] have also studied plasma levels of Lp(a) and several ox-Lp(a) markers 
immediately before and serially up to 6 months after percutaneous coronary intervention 
(PCI). PCI resulted in acute elevations of native, oxidized Lp(a) and Lp(a)-IC levels in both 
ACS and stable CAD patients, and decrease of ox-Lp(a)-Ab (Figure 4). Interestingly, the 
change of ox-Lp(a) during PCI was found to correlate with the extent of angiographically 
documented disease only in ACS patients, while not in stable CAD. Tsimikas et al. [51] also 
reported that indirect and direct plasma markers of oxidized phospholipids (ox-PL) showed 
significant temporal elevations following ACS, but not in patients with stable CAD or in 
subjects without CAD. These observations indicate one possibility that ACS episode causes 
sustained rise of ox-Lp(a), and further support the hypothesis that ox-Lp(a) is present in 
ruptured or permeable plaques and is released into the circulation by PCI.  
The above results are also supported by the studies about ox-PL, which have demonstrated 
convincingly that a key ox-PL is preferentially associated with Lp(a) [52] and correlates with 
both the presence and extent of angiographically documented CAD [40, 53], and their 
concentrations increase after ACS [51] and immediately after PCI [54]. 
8. The source of plasma ox-Lp(a)  
Oxidized lipoprotein results from exposure of lipoprotein to oxidizing species, such as 
superoxide anion and hydrogen peroxide derived from all cells present in the artery wall, 
particularly macrophages, as well as enzymes such as lipoxygenases and products of 
myeloperoxidase, resulting in oxidation of the lipid and protein components [55].  
The source of plasma ox-Lp(a) is unknown. Holvoet et al. [56] isolated ox-LDL from the 
plasma of patients with post-transplant CAD and analyzed its characteristics, which 
suggested that it did not originate from extensive metal ion-induced oxidation of LDL but 
that it might be generated by cell-associated oxidative enzymatic activity in the arterial wall. 
It was also demonstrated in animal models that the oxidation of LDL indeed occurs in the 
arterial wall and not in the blood [57].  
Studies have shown that increased ox-Lp(a) level in stable CAD and especially in ACS is 
associate with the severity of angiographically documented disease in ACS, while not in 
stable CAD [48, 49]. Similarly, the extent of CAD was found related with the change of ox-
Lp(a) levels before and after PCI in the ACS and stable CAD patients [50]. These above 
results suggested that ox-Lp(a) particles in the blood came from the arterial wall, such as 
directly released from ruptured or permeable plaques. It was also possible that oxidation-
specific epitopes generated in the arterial intima, such as oxidized phospholipids, might 
have been transported by some mechanisms to Lp(a) acceptors, or might move between 
LDL and Lp(a).  
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Elevated Lp(a) level may also result in increased circulating ox-Lp(a). Ox-Lp(a) is found 
related with Lp(a), which shows that more Lp(a) in subjects with high Lp(a) has chance to be 
oxidized in vivo, resulting in strong immune response and leading to the formation of Lp(a)-
IC [36, 47]. In addition, Lp(a) is known to act as an acute-phase reactant in patients with 
ACS. It has also been found increased Lp(a) and ox-Lp(a) levels are positively related with 
C-reactive protein in patients with rheumatoid arthritis [47], which suggests that 
inflammation promotes Lp(a) synthesis and its oxidation.  
One of important problems remaining to be answered is whether the response to oxidized 
lipoprotein plays an initiating or a contributing role in the development of atherosclerosis. 
To answer this question through clinical studies, one major problem is the difficulty 
encountered in defining atherosclerosis-free individuals. The results that high levels of anti-
ox-LDL antibodies and LDL-IC are present in individuals with confirmed atherosclerosis 
suggest that the immune response to ox-LDL may be a secondary phenomenon, possible 
contributing to the development of atherosclerosis. However, the studies have shown that 
ox-Lp(a) and Lp(a)-IC are present in all the healthy children and especially in newborns, 
and that anti-ox-LDL antibodies and LDL-IC are easily detectable in asymptomatic young 
adults and children [45, 46, 58], for early arterial lesions may not present in all the children, 
which suggest that the immune response to modified lipoproteins could appear very early 
in the process, perhaps being one of the initiating factors. In fact, oxidative stress has been 
reported to be present early in pregnancy and children, and to be associated with arterial 
dysfunction and enhanced intima-media thickness [43, 44]. In general, it has been accepted 
that lipoprotein traverses the subendothelial space where it becomes oxidized, and may 
induce endothelial dysfunction, one of the earliest manifestations of atherosclerosis. In vitro 
and in vivo studies have shown that ox-LDL promotes endothelial cell toxicity and 
vasoconstriction [59]. The above studies suggest that part of lipoproteins have been oxidized 
before they traverse the subendothelial space, prior to advanced lesion formation, and 
directly participating in the development of atherosclerosis. 
9. Lp(a) immune complexes and β2-glycoprotein I complexes with Lp(a)  
It has been proposed that modified lipoproteins might contribute to atherogenesis by 
another mechanism-their ability to trigger an immune response leading to the production 
of autoantibodies and subsequently to the formation of IC. Some studies have shown that 
incubation of human monocyte-derived macrophages with insoluble or soluble LDL-IC 
induces foam cell formation in vitro more efficiently than any other known mechanism 
[60-62]. The pathogenic role of LDL-IC in vivo is also supported, and the studies have 
shown that plasma LDL-IC level increases in patients with CAD [63, 19] and that the 
cholesterol content of LDL-IC is a powerful discriminator for the presence of coronary 
atherosclerosis [20].  
Lp(a) might also trigger an immune response leading to the production of autoantibodies 
and subsequently to the formation of IC. Interestingly, it has been found that Lp(a)-IC was 
present in both the plasma of patients with CAD and control, and Lp(a)-IC level increased 
in the CAD patients [64]. Furthermore, Wang et al. [65] studied the plasma Lp(a) and 
Lp(a)-IC levels in 232 subjects with various dyslipidemias. This study showed that both 
Lp(a) and Lp(a)-IC levels were different in various types of primary hyperlipidemia. 
Moreover, it was found that plasma Lp(a)-IC levels represented the similar distribution to 
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that of Lp(a). In fact, both antibodies against oxidized apo(a) and apoB in vivo can form 
immune complexes with oxidative apo(a) or apoB of Lp(a). In addition, not a parallel 
increment between Lp(a)-IC and LDL-IC levels was found according to Lp(a) cutoff level 
(especially Lp(a)<300mg/l), which suggested that Lp(a)-IC level might act as an 
additional predictor of premature CAD [64]. Recently, Wang et al. have also found that 
incubation of human monocyte-derived macrophages with Lp(a)-IC induces foam cell 
formation by Fcγ receptor pathway in vitro.  
It was reported that β2-GPI was present in the sera of autoimmune diseases and was 
characterized by its ability to bind to negative charged molecules, including lipoproteins 
[66-69]. Recently, studies showed that β2-GPI specifically interacted with LDL as well as ox-
LDL, and formed complexes in the intima of atherosclerotic lesions, and then, these 
complexes were taken up by macrophages via anti-β2-GPI autoantibody-mediated 
phagocytosis, contributing to the development of atherosclerosis [70]. In vitro studies also 
demonstrated that β2-GPI bound Lp(a) with high affinity [71, 72], suggesting that β2-GPI 
might bind Lp(a) to form complexes of β2-GPI with Lp(a) [β2-GPI-Lp(a)] in vivo. 
Furthermore, preliminary data suggest that additional ox-PL are present in the lipid phase 
of Lp(a) (Figure 5) [73]. 
Our studies have found that β2-GPI-Lp(a) indeed existed in serum samples, and that β2-GPI-
Lp(a) as well as ox-Lp(a) concentrations were significantly elevated in systemic lupus 
erythematosus (SLE) patients with excessive cardiovascular events [74], and in active 
rheumatoid arthritis (RA) patients [75]. Furthermore, β2-GPI-Lp(a) levels were found 
increased in both the patients with ACS and stable CAD. The logistic regression analysis of 
risk factors revealed that the presence of β2-GPI-Lp(a) as well as ox-Lp(a) or Lp(a) was a 
strong risk factor for stable CAD, and especially for ACS, suggesting that the β2-GPI-Lp(a) 
complexes might act as an additional predictor of atherosclerosis [76].  
An important role in the accumulation of ox-PL on Lp(a) may also be played by β2-GPI, 
which binds to the kringle IV domain of apo(a) [71], as well as to anionic phospholipids and 
ox-PL [77]. Importantly, high β2-GPI levels were also found on the Lp(a) of CAD patients, 
whereas removal of apo(a) from the Lp(a) particles of these patients led to reduction of the 
β2-GPI levels and to increase in the lipoprotein-associated phospholipase A2 (Lp-PLA2) 
catalytic efficiency. Substrates for Lp-PLA2 contain oxidatively fragmented residues at the 
sn-2 position (ox-PL). Thus, the higher amounts of β2-GPI on the Lp(a) of CAD patients 
could contribute to the sequestration of ox-PL on the surface of Lp(a) [78]. 
10. Conclusions 
In summary, Lp(a) might be oxidatively modified in vivo, which causes marked changes in 
the structure and biological properties of Lp(a). Oxidatively modified Lp(a) has more 
pathogenicity in both formation of foam cells and fibrinolysis. Elevated plasma 
concentrations of ox-Lp(a) reflect the presence and extent of angiographically documented 
CAD, especially clinically expressed in ACS. The elevated plasma concentrations of ox-Lp(a) 
suggest plaque instability and may be useful for the identification of patients with ACS. The 
assay of ox-Lp(a) may provide a new approach to investigate the causal role of ox-Lp(a) in 
atherosclerotic cardiovascular disease in a prospective study and to explore the exact 
pathogenic role of ox-Lp(a). 
www.intechopen.com
 
Coronary Artery Disease – New Insights and Novel Approaches 
 
56
11. Annex 
 
 
 
 
 
 
 
 
 
 
Lp(a) is an LDL-like particle composed of a lipid core (cholesteryl esters; triglycerides) encapsulated by 
a surface layer (phospholipid; free cholesterol). As with LDL, Lp(a) contains one molecule of apoB, 
linked to the apo(a) by a single disulfide bond. The apo(a) moiety consists of a single copy of kringles 
(K) 4, types 1 and 3 through 10, kringle 5, and a protease domain analogous to the structure of 
plasminogen. Lp(a) always has multiple copies of kringle 4, type 2 contributing to the abundant 
heterogeneity of the molecule. 
Fig. 1. Schematic Model of Lp(a) Structure.  
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No difference of their levels was found among the age groups. 
Fig. 2. Mean levels of Lp(a), ox-Lp(a) and Lp(a)-IC in each of the 13 year groups in the 747 
children. 
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Ox-Lp(a)1: detected by anti-ox-Lp(a); ox-Lp(a)2: detected by anti-ox-LDL. 
Fig. 3. Receiver-operating characteristic curve analysis of ox-Lp(a) and Lp(a) levels in 
patients with ACS and stable CAD.  
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The change is expressed as mean percent change from pre-PCI levels. * P<0.001 by ANOVA. Lp(a): 
P<0.001 compared with before and 6-month time points; P<0.05 compared with 2- and 3-day time 
points. Ox-Lp(a): P<0.001 compared with before, 3-day, and 6-month time point; P<0.01 compared with 
2-day time point. Lp(a)-IC: P<0.05 compared with before, 3-day, and 6-month time point. Ox-Lp(a)-Ab: 
P<0.001 compared with before and 6-month time points; P<0.01 compared with 2- and 3-day time 
points. 
Fig. 4. Changes of Lp(a), ox-Lp(a), Lp(a)-IC, and ox-Lp(a)-Ab levels after PCI.  
 
Lp(a) of CAD patients contains higher levels of β2-GPI and ox-PL and significantly less amount of Lp-
PLA2 mass compared with Lp(a) from normal plasma. 
Fig. 5. Association of Lp-PLA2 and ox-PL with Lp(a) in normal plasma as well as in plasma 
of patients with CAD.  
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